NICE Recommends Bayer’s Nubeqa for Prostate Cancer
The UK’s National Institute of Health and Care Excellence (NICE) has recommended Bayer’s Nubeqa (darolutamide), an oral androgen receptor inhibitor, in conjunction with androgen deprivation therapy (ADT) for the treatment of men with hormone-relapsed prostate cancer at high risk of developing metastatic disease.
The recommendation for the drug’s use by the National Health Service (NHS) was supported by data from a phase 3 trial demonstrating Nubeqa and ADT increased metastasis-free survival by 40.4 months vs. 18.4 months for the placebo plus ADT arm. Participants taking Nubeqa saw a 31 percent reduction in mortality.
Prostate cancer is the most common cancer diagnosed in men in the UK, with 48,000 new cases reported annually. Men with this form of prostate cancer often have no symptoms, so it is essential they get early treatment to stop the spread of cancer, said Amit Bahl, an oncologist with the University Hospitals Bristol NHS Foundation Trust.